Vertex Pharmaceuticals Incorporated (VRTX) Q1 2020 Earnings Results

Vertex Pharmaceuticals Beats on EPS, Stock Down 2.3%

Vertex Pharmaceuticals reported strong earnings per share, exceeding expectations significantly. However, the stock fell by 2.3% in reaction, likely due to the absence of revenue figures and guidance. Investors may be cautious as they await more detailed financial insights in future reports.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$2.56	N/A	+64.10%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the earnings per share results, highlighting their commitment to future growth. They acknowledged current market challenges but maintained a positive outlook.

We are pleased with our EPS performance this quarter.

Despite the challenges, we remain focused on our long-term goals.

Vertex Pharmaceuticals Beats on EPS, Stock Down 2.3%

Key numbers

Management commentary

Vertex Pharmaceuticals Incorporated

More earnings this week

Vertex Pharmaceuticals Beats on EPS, Stock Down 2.3%

Key numbers

Management commentary